Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

RTY-694 is a potent, orally active ABCB4/BSEP positive functional modulator (PFM) that improves bile composition and enhances bile flowThe ...

Three years after raising $100 million in series A funds, the Atlas Venture-backed biotech has chosen a lead drug candidate.

High levels of fat in your liver increases your risk of serious health problems, such as diabetes, high blood pressure and kidney disease ...

Kidney scarring, or fibrosis, is an irreversible condition that can lead to chronic kidney disease (CKD) by damaging the ...

In cases of pulmonary fibrosis attributable to interstitial lung disease, whether the aetiology is known or unknown, the ...

The National Institutes of Health (NIH) has awarded $2.9 million to Arkansas Children’s Research Institute (ACRI) to examine how a critical therapy for patients with cystic fibrosis (CF) might ...

Positive results from the MAESTRO-NASH OUTCOMES study could make resmetirom the first medication approved for patients with compensated NASH ...

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with ...

As one in three Indians gets diagnosed with non-alcoholic fatty liver, a look at how lifestyle choices can make a difference.

A new discovery about how the liver flushes cholesterol from the body could lead to more effective treatments for cardiovascular disease – the leading cause of death worldwideNew Delhi: University of ...